EGLN2 and cancer: In the year 2012, Zhu et al. firstly investigated the association between a 4‐bp indel polymorphism (rs10680577) within the distal promoter of EGLN2 and cancer risk based on two independent case–control studies, and found that the deletion allele of rs10680577 polymorphism was significantly associated with increased risk of hepatocellular carcinoma.